In our final set of experiments, we demonstrated for the first time the gene editing of mobilized PB CD34+ cells directly obtained from FA‐A patients, the target population currently considered for the gene therapy of several inherited diseases, including FA (see review in Tolar et al, 2012). The gene discussed is CD34; the disease is Friedreich ataxia.